MOSCOW (MRC) -- Evonik and Halchemix Canada are pleased to announce the launch of a strategic partnership for the promotion of Evonik’s rumen-protected methionine product Mepron® in the Canadian market, as per the company's press release.
The agreement will see Halchemix become the exclusive distributor of Mepron® in Canada. The product is a superior methionine source that helps to boost milk production and reduce feed costs for the dairy industry.
Ken O'Halloran, Evonik’s Regional Vice President, North America, said: "Halchemix is well established in the Canadian market as a provider of well-researched feed additives, making them an ideal partner. Their products include amino acids, phytase, enzymes, and a dairy product line that includes rumen protected lysine and DCAD products."
The use of Mepron makes it easy to balance the ration for amino acids. This results in better herd health thanks to improved liver function, lower inflammation and less oxidative stress; higher dry matter intake followed by higher energy-corrected milk (ECM) yield; higher profitability (Income Over Feed Costs); lower nitrogen emissions and higher weaning weights of calves.
As MRC reported earlier, Evonik Industries AG combined its isophorone chemistry and epoxy curing agents business in the new Crosslinkers Business Line effective July 1, 2017. The newly formed Business Line, headed by Min Chong, is part of the Resource Efficiency Segment
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of EUR2.6 billion.
MRC